US Stock MarketDetailed Quotes

PLX Protalix Biotherapeutics

Watchlist
  • 1.710
  • 0.0000.00%
Trading Dec 19 10:42 ET
125.91MMarket Cap-11.40P/E (TTM)

Protalix Biotherapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
73.60%17.96M
-61.59%13.47M
-60.91%3.75M
37.48%65.49M
21.69%10.49M
-27.06%10.35M
300.72%35.08M
-40.39%9.59M
24.22%47.64M
0.80%8.62M
Operating revenue
73.60%17.96M
-61.59%13.47M
-60.91%3.75M
37.48%65.49M
21.69%10.49M
-27.06%10.35M
300.72%35.08M
-40.39%9.59M
24.22%47.64M
0.80%8.62M
Cost of revenue
71.16%8.38M
53.81%9.46M
-15.66%2.6M
17.30%22.98M
269.46%8.86M
-30.83%4.89M
50.43%6.15M
-48.87%3.09M
19.84%19.59M
-23.86%2.4M
Gross profit
75.79%9.58M
-86.11%4.02M
-82.38%1.15M
51.58%42.51M
-73.79%1.63M
-23.31%5.45M
519.95%28.93M
-35.30%6.5M
27.48%28.05M
15.16%6.22M
Operating expense
-23.79%5.59M
-24.23%6.45M
-33.03%6M
-21.94%32.05M
-16.87%7.25M
-28.29%7.34M
-16.53%8.51M
-24.82%8.96M
-3.30%41.06M
-21.54%8.72M
Selling and administrative expenses
-29.29%2.6M
-13.57%3.48M
0.00%3.12M
27.73%14.96M
33.73%4.14M
28.86%3.67M
54.39%4.03M
-1.24%3.12M
-8.00%11.71M
-10.62%3.1M
Research and development costs
-18.29%3M
-33.83%2.96M
-50.62%2.89M
-41.76%17.09M
-44.77%3.1M
-50.32%3.67M
-40.96%4.48M
-33.31%5.85M
-1.29%29.35M
-26.49%5.62M
Operating profit
311.50%3.99M
-111.88%-2.43M
-97.48%-4.86M
180.37%10.46M
-125.05%-5.62M
39.62%-1.89M
469.68%20.42M
-31.50%-2.46M
36.40%-13.01M
56.27%-2.5M
Net non-operating interest income expense
-188.10%-148K
120.03%155K
125.79%123K
-36.95%-1.89M
-13.43%-811K
138.01%168K
-507.37%-774K
-14.66%-477K
80.58%-1.38M
21.43%-715K
Non-operating interest income
-75.96%151K
-1.69%522K
198.26%513K
12.22%1.29M
43.08%-37K
218.78%628K
-34.69%531K
-14.85%172K
185.79%1.15M
-3,150.00%-65K
Non-operating interest expense
-35.00%299K
-71.88%367K
-39.91%390K
25.74%3.18M
19.08%774K
-28.01%460K
109.47%1.31M
5.02%649K
-66.37%2.53M
-28.41%650K
Other net income (expense)
Income before tax
323.56%3.84M
-111.56%-2.27M
-61.21%-4.73M
159.50%8.57M
-100.19%-6.43M
51.81%-1.72M
468.34%19.65M
-28.43%-2.94M
47.80%-14.4M
51.85%-3.21M
Income tax
356.39%607K
-122.40%-69K
-170.77%-138K
-52.08%254K
-172.08%-382K
133K
308K
195K
530K
530K
Net income
274.73%3.24M
-111.39%-2.2M
-46.76%-4.6M
155.68%8.31M
-61.60%-6.04M
48.08%-1.85M
462.56%19.34M
-36.96%-3.13M
45.88%-14.93M
43.90%-3.74M
Net income continuous Operations
274.73%3.24M
-111.39%-2.2M
-46.76%-4.6M
155.68%8.31M
-61.60%-6.04M
48.08%-1.85M
462.56%19.34M
-36.96%-3.13M
45.88%-14.93M
43.90%-3.74M
Minority interest income
Net income attributable to the parent company
274.73%3.24M
-111.39%-2.2M
-46.76%-4.6M
155.68%8.31M
-61.60%-6.04M
48.08%-1.85M
462.56%19.34M
-36.96%-3.13M
45.88%-14.93M
43.90%-3.74M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
274.73%3.24M
-111.39%-2.2M
-46.76%-4.6M
155.68%8.31M
-61.60%-6.04M
48.08%-1.85M
462.56%19.34M
-36.96%-3.13M
45.88%-14.93M
43.90%-3.74M
Basic earnings per share
233.33%0.04
-110.34%-0.03
-20.00%-0.06
138.71%0.12
-42.86%-0.1
57.14%-0.03
363.64%0.29
0.00%-0.05
50.00%-0.31
50.00%-0.07
Diluted earnings per share
175.00%0.03
-114.29%-0.03
-20.00%-0.06
129.03%0.09
-42.86%-0.1
42.86%-0.04
290.91%0.21
0.00%-0.05
50.00%-0.31
50.00%-0.07
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
--
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 73.60%17.96M-61.59%13.47M-60.91%3.75M37.48%65.49M21.69%10.49M-27.06%10.35M300.72%35.08M-40.39%9.59M24.22%47.64M0.80%8.62M
Operating revenue 73.60%17.96M-61.59%13.47M-60.91%3.75M37.48%65.49M21.69%10.49M-27.06%10.35M300.72%35.08M-40.39%9.59M24.22%47.64M0.80%8.62M
Cost of revenue 71.16%8.38M53.81%9.46M-15.66%2.6M17.30%22.98M269.46%8.86M-30.83%4.89M50.43%6.15M-48.87%3.09M19.84%19.59M-23.86%2.4M
Gross profit 75.79%9.58M-86.11%4.02M-82.38%1.15M51.58%42.51M-73.79%1.63M-23.31%5.45M519.95%28.93M-35.30%6.5M27.48%28.05M15.16%6.22M
Operating expense -23.79%5.59M-24.23%6.45M-33.03%6M-21.94%32.05M-16.87%7.25M-28.29%7.34M-16.53%8.51M-24.82%8.96M-3.30%41.06M-21.54%8.72M
Selling and administrative expenses -29.29%2.6M-13.57%3.48M0.00%3.12M27.73%14.96M33.73%4.14M28.86%3.67M54.39%4.03M-1.24%3.12M-8.00%11.71M-10.62%3.1M
Research and development costs -18.29%3M-33.83%2.96M-50.62%2.89M-41.76%17.09M-44.77%3.1M-50.32%3.67M-40.96%4.48M-33.31%5.85M-1.29%29.35M-26.49%5.62M
Operating profit 311.50%3.99M-111.88%-2.43M-97.48%-4.86M180.37%10.46M-125.05%-5.62M39.62%-1.89M469.68%20.42M-31.50%-2.46M36.40%-13.01M56.27%-2.5M
Net non-operating interest income expense -188.10%-148K120.03%155K125.79%123K-36.95%-1.89M-13.43%-811K138.01%168K-507.37%-774K-14.66%-477K80.58%-1.38M21.43%-715K
Non-operating interest income -75.96%151K-1.69%522K198.26%513K12.22%1.29M43.08%-37K218.78%628K-34.69%531K-14.85%172K185.79%1.15M-3,150.00%-65K
Non-operating interest expense -35.00%299K-71.88%367K-39.91%390K25.74%3.18M19.08%774K-28.01%460K109.47%1.31M5.02%649K-66.37%2.53M-28.41%650K
Other net income (expense)
Income before tax 323.56%3.84M-111.56%-2.27M-61.21%-4.73M159.50%8.57M-100.19%-6.43M51.81%-1.72M468.34%19.65M-28.43%-2.94M47.80%-14.4M51.85%-3.21M
Income tax 356.39%607K-122.40%-69K-170.77%-138K-52.08%254K-172.08%-382K133K308K195K530K530K
Net income 274.73%3.24M-111.39%-2.2M-46.76%-4.6M155.68%8.31M-61.60%-6.04M48.08%-1.85M462.56%19.34M-36.96%-3.13M45.88%-14.93M43.90%-3.74M
Net income continuous Operations 274.73%3.24M-111.39%-2.2M-46.76%-4.6M155.68%8.31M-61.60%-6.04M48.08%-1.85M462.56%19.34M-36.96%-3.13M45.88%-14.93M43.90%-3.74M
Minority interest income
Net income attributable to the parent company 274.73%3.24M-111.39%-2.2M-46.76%-4.6M155.68%8.31M-61.60%-6.04M48.08%-1.85M462.56%19.34M-36.96%-3.13M45.88%-14.93M43.90%-3.74M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 274.73%3.24M-111.39%-2.2M-46.76%-4.6M155.68%8.31M-61.60%-6.04M48.08%-1.85M462.56%19.34M-36.96%-3.13M45.88%-14.93M43.90%-3.74M
Basic earnings per share 233.33%0.04-110.34%-0.03-20.00%-0.06138.71%0.12-42.86%-0.157.14%-0.03363.64%0.290.00%-0.0550.00%-0.3150.00%-0.07
Diluted earnings per share 175.00%0.03-114.29%-0.03-20.00%-0.06129.03%0.09-42.86%-0.142.86%-0.04290.91%0.210.00%-0.0550.00%-0.3150.00%-0.07
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion------------
Trending US Stocks
Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Symbol Mini Chart % Chg
Halozyme Therapeutics
HALO
+1.84%
Dorian LPG
LPG
+1.33%
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
+1.08%
Teradata Corp
TDC
+0.98%
Hutchmed (China)
HCM
+0.83%

Unlock the Full List